Biotech Values

[oc631]

Since the demise of IDX320, IDIX doesn’t have a protease inhibitor in preclinical or clinical development; all they have are a couple of PI candidates to take into preclinical development if additional pre-preclinical work suggests that it’s worth doing.

Right. My point still being they are spending money and using resources to develop a candidate in that class.

If the FDA does not quickly lift the partial clinical hold on IDX184 after reviewing the 28-day data from the first 30 patients in the phase-2b trial, IDIX could become bait for a takeunder buyout.

When/if they get that hold lifted they will need to do at least 2-3 more phase 2 studies before IDX-184 can move into late stage testing. McBio might be right about 184 being damaged goods.